Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 11, 2026, 12:17 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 429 matching trials from the live ClinicalTrials.gov search.
Filters: "treatment-resistant depression" Condition: Depression Clear all
Completed Not applicable Interventional Results available

Neuroimaging in Patients Undergoing TMS for Depression

NCT02974296
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
transcranial magnetic stimulation
Device
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 60 Years
Enrollment
33 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Oct 23, 2020 · Synced Oct 11, 2026, 12:17 PM EDT
Recruiting Not applicable Interventional

Spaced Transcranial Direct Current Stimulation for Treatment-Resistant Depression: A Home-Based Feasibility and Safety Study

NCT07217223
View directory record Official record
Conditions
Treatment Resistant Depression (TRD), Major Depressive Disorder (MDD)
Interventions
Spaced Transcranial Direct Current Stimulation (tDCS)
Device
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years to 85 Years
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Sep 15, 2026 · Synced Oct 11, 2026, 12:17 PM EDT
Recruiting Not applicable Interventional

Intracranial Investigation of Neural Circuity Underlying Human Mood

NCT05871372
View directory record Official record
Conditions
Depression, Epilepsy
Interventions
Brain Stimulation, sEEG Stimulation
Device
Lead sponsor
Baylor College of Medicine
Other
Eligibility
21 Years to 70 Years
Enrollment
58 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 4, 2026 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Phase 2 Interventional

Mechanistic Evaluation of Response in TRD (MERIT)

NCT04608396
View directory record Official record
Conditions
Treatment Resistant Depression, Major Depressive Disorder
Interventions
AXS-05, Placebo
Drug
Lead sponsor
Axsome Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
20
States / cities
Little Rock, Arkansas • Redlands, California • Sherman Oaks, California + 17 more
Source: ClinicalTrials.gov public record
Updated Jul 12, 2022 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Results available

Inhaled Nitrous Oxide for Treatment-Resistant Depression: Optimizing Dosing Strategies

NCT03283670
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
Nitrous Oxide 25%, Nitrous Oxide 50%, Placebo Gas
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 4, 2022 · Synced Oct 11, 2026, 12:17 PM EDT
Active, not recruiting Not applicable Interventional

Rapid Acting Transcranial Magnetic Stimulation

NCT04739969
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Active TBS-DLPFC, Sham TBS-DLPFC
Device
Lead sponsor
Stanford University
Other
Eligibility
22 Years to 65 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated May 6, 2025 · Synced Oct 11, 2026, 12:17 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Computational Psychiatric Approach to Depression

NCT04189939
View directory record Official record
Conditions
Depression, Treatment Resistant Depression
Interventions
clinical assessments
Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 85 Years
Enrollment
128 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 6, 2024 · Synced Oct 11, 2026, 12:17 PM EDT
Recruiting Not applicable Interventional

Tractography Guided Subcallosal Cingulate Deep Brain Stimulation for Treatment Resistant Depression

NCT03952962
View directory record Official record
Conditions
Treatment Resistant Depression, Undergoing Deep Brain Stimulation (DBS) Surgery
Interventions
Abbott Laboratories Infinity™ implantable deep brain stimulation system
Device
Lead sponsor
Nader Pouratian
Other
Eligibility
21 Years to 70 Years
Enrollment
12 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jul 15, 2026 · Synced Oct 11, 2026, 12:17 PM EDT
Recruiting Phase 3 Interventional

Lumateperone for Late-Life Depression

NCT07623135
View directory record Official record
Conditions
Treatment Resistant Depression (TRD), Late Life Depression (LLD), Depression / Major Depressive Disorder
Interventions
Lumateperone, Placebo
Drug
Lead sponsor
Eric Lenze
Other
Eligibility
60 Years and older
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
2
States / cities
Tucson, Arizona • St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Sep 16, 2026 · Synced Oct 11, 2026, 12:17 PM EDT
Not yet recruiting Phase 1Phase 2 Interventional

Psilocybin Assisted Psychotherapy for Treatment Resistant Depression and Co-occurring Substance Use Disorder

NCT07499583
View directory record Official record
Conditions
Treatment Resistant Depression, Substance Use Disorders
Interventions
Psilocybin
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2031
U.S. locations
2
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 30, 2026 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Not applicable Interventional

Comparing Acupuncture, BioModulator, and Transcutaneous Electrical Nerve Stimulation for Symptomatic Treatment of Chronic Pain.

NCT01752010
View directory record Official record
Conditions
Chronic Pain, Depression, PTSD Symptoms, Sleep
Interventions
Traditional Chinese Acupuncture, Tennant™ Biomodulator Treatment, Transcutaneous electrical nerve stimulation (TENS) Treatment
Other · Device
Lead sponsor
Samueli Institute for Information Biology
Other
Eligibility
18 Years to 60 Years
Enrollment
98 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Fort Sam Houston, Texas
Source: ClinicalTrials.gov public record
Updated May 19, 2015 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Not applicable Interventional

Cognitive Therapy to Sustain the Antidepressant Effects of Intravenous Ketamine in Treatment-resistant Depression

NCT03027362
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Cognitive behavioral therapy (CBT) and medication, Psychoeducation and medication
Other
Lead sponsor
Yale University
Other
Eligibility
18 Years to 65 Years
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 5, 2020 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Not applicable Interventional Results available

Improving Outcomes for Individuals With Serious Mental Illness and Diabetes

NCT01410357
View directory record Official record
Conditions
Diabetes Mellitus, Bipolar Disorder, Depression, Psychotic Disorders, Schizophrenia
Interventions
Targeted Training in Illness Management (TTIM)
Behavioral
Lead sponsor
Case Western Reserve University
Other
Eligibility
18 Years and older
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Oct 4, 2017 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Results available

Abnormal Ventilatory Response to Carbon Dioxide: a Potential Biomarker for Seizure Induced Respiratory Depression & Modification by SSRI

NCT02929667
View directory record Official record
Conditions
Epilepsy, SUDEP
Interventions
Fluoxetine, Placebo
Drug
Lead sponsor
Rup Kamal Sainju
Other
Eligibility
18 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
2
States / cities
Iowa City, Iowa
Source: ClinicalTrials.gov public record
Updated May 4, 2020 · Synced Oct 11, 2026, 12:17 PM EDT
Withdrawn Phase 4 Interventional

VA Aripiprazole vs Esketamine for Treatment Resistant Depression

NCT05554627
View directory record Official record
Conditions
Depressive Disorder, Major
Interventions
Esketamine, Aripiprazole
Drug
Lead sponsor
VA Office of Research and Development
Federal
Eligibility
18 Years to 74 Years
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023
U.S. locations
26
States / cities
Tuscaloosa, Alabama • Phoenix, Arizona • Little Rock, Arkansas + 22 more
Source: ClinicalTrials.gov public record
Updated Jan 5, 2024 · Synced Oct 11, 2026, 12:17 PM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

NMDA Receptor Antagonist Nitrous Oxide Targets Affective Brain Circuits

NCT02994433
View directory record Official record
Conditions
Depressive Disorder, Major, Depressive Disorder, Treatment-Resistant
Interventions
Nitrous Oxide, Placebo gas, MRI
Drug · Device
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years to 65 Years
Enrollment
60 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2027
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 29, 2026 · Synced Oct 11, 2026, 12:17 PM EDT
Terminated Phase 4 Interventional Accepts healthy volunteers Results available

PET Biomarkers in Treatment Resistant Depression

NCT01031810
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
tranylcypromine
Drug
Lead sponsor
New York State Psychiatric Institute
Other
Eligibility
18 Years to 65 Years
Enrollment
13 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Sep 18, 2014 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Not applicable Interventional Results available

Riluzole in the Treatment of Bipolar Depression

NCT00544544
View directory record Official record
Conditions
Bipolar Depression
Interventions
Riluzole
Drug
Lead sponsor
Mclean Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
1
States / cities
Belmont, Massachusetts
Source: ClinicalTrials.gov public record
Updated Aug 7, 2018 · Synced Oct 11, 2026, 12:17 PM EDT
Recruiting Phase 2 Interventional

Intravenous Ketamine for Treatment-Resistant Depression

NCT06668571
View directory record Official record
Conditions
Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions
Ketamine, Normal Saline
Drug
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Rochester, Minnesota
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 11, 2026, 12:17 PM EDT
Active, not recruiting Not applicable Interventional

Deep Brain Stimulation (DBS) Therapy for Treatment Resistant Depression

NCT02046330
View directory record Official record
Conditions
Major Depressive Disorder, Treatment Resistant Depression
Interventions
Deep Brain Stimulation Model 3387 Model 3389
Device
Lead sponsor
The University of Texas Health Science Center, Houston
Other
Eligibility
22 Years to 70 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2027
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Feb 23, 2026 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Not applicable Interventional

Practicing Alternative Techniques to Heal From Depression: The PATH-D Study

NCT00871299
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
Mindfulness Based Cognitive Therapy, Health Enhancement Program and medication management
Behavioral
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2014
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Dec 2, 2014 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Phase 1 Interventional

Multiple Ascending Dose Phase 1 Study of ALA-3000

NCT06965569
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
ALA-3000, Placebo, escitalopram, sertraline, duloxetine or venlafaxine XR
Drug
Lead sponsor
Alar Pharmaceuticals Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
4
States / cities
Little Rock, Arkansas • St Louis, Missouri • Eatontown, New Jersey + 1 more
Source: ClinicalTrials.gov public record
Updated Dec 31, 2025 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Phase 2 Interventional Results available

The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression

NCT03775200
View directory record Official record
Conditions
Treatment Resistant Depression
Interventions
Psilocybin
Drug
Lead sponsor
COMPASS Pathways
Industry
Eligibility
18 Years and older
Enrollment
233 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2021
U.S. locations
8
States / cities
La Jolla, California • San Diego, California • Stanford, California + 5 more
Source: ClinicalTrials.gov public record
Updated Apr 24, 2023 · Synced Oct 11, 2026, 12:17 PM EDT
Completed Phase 4 Interventional

A Study of 6(S)-5-MTHF Among Serotonin Reuptake Inhibitor(SSRI)-Resistant Outpatients With Major Depressive Disorder (MDD)

NCT00321152
View directory record Official record
Conditions
Major Depressive Disorder
Interventions
6(S)-5-MTHF (a Medical Food)
Other
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years to 65 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
11
States / cities
San Diego, California • Chicago, Illinois • New Orleans, Louisiana + 8 more
Source: ClinicalTrials.gov public record
Updated Jun 8, 2010 · Synced Oct 11, 2026, 12:17 PM EDT